TrialHuman vaccines & immunotherapeutics2019

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study.

Yuemei Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.